Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00046319 | Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension | PHASE2 | COMPLETED | 60 | — | — | Sep 1, 2002 | Jun 1, 2003 | Apr 16, 2009 | 21 | United States, Australia +4 |
| Name | Type | Description |
|---|---|---|
| BSF 208075 | DRUG | - |
--Disease Characteristics-- * Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of disease (e.g., mixed connective tissue disease, systemic lupus erythematosus, systemic sclerosis, or overlap syndrome), anorexigen use, or human immunodeficiency virus (HIV) infection at th...